Inhibition of human aldose reductase-like protein (AKR1B10) by α- and γ-mangostins, major components of pericarps of mangosteen

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 11, 2012, Pages 2075-2080

  Soda, Midori ^a   Endo, Satoshi ^a   Matsunaga, Toshiyuki ^a   Zhao, Hai Tao ^b   El Kabbani, Ossama ^b   Iinuma, Munekazu ^c   Yamamura, Keiko ^a   Hara, Akira ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b AICHI GAKUIN UNIVERSITY   (Japan)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Aldo keto reductase 1B10; Aldose reductase; Anti cancer property; Mangostin; Molecular docking; Xanthone

Indexed keywords

ALDEHYDE REDUCTASE; ALPHA MANGOSTIN; GAMMA MANGOSTIN; GLYCINE; MANGOSTINONE; PHENYLALANINE; PROTEIN AKR1B10; TRYPTOPHAN; UNCLASSIFIED DRUG; VALINE; XANTHONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG DETERMINATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; GARCINIA MANGOSTANA; MANGOSTEEN; MOLECULAR DOCKING; NONHUMAN; PERICARP; PROTEIN BINDING; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS;

ALDEHYDE REDUCTASE; ANTINEOPLASTIC AGENTS; FRUIT; GARCINIA MANGOSTANA; HUMANS; MOLECULAR DOCKING SIMULATION; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; XANTHONES;

EID: 84869211190     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00538     Document Type: Article

References (40)

1. Cao D, Fan ST, Chung SS. Identification and characterization of a novel human aldose reductase-like gene. J. Biol. Chem., 273, 11429-11435 (1998).
2. Fukumoto S, Yamauchi N, Moriguchi H, Hippo Y, Watanabe A, Shibahara J, Taniguchi H, Ishikawa S, Ito H, Yamamoto S, Iwanari H, Hironaka M, Ishikawa Y, Niki T, Sohara Y, Kodama T, Nishimura M, Fukayama M, Dosaka-Akita H, Aburatani H. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin. Cancer Res., 11, 1776-1785 (2005).
3. Yoshitake H, Takahashi M, Ishikawa H, Nojima M, Iwanari H, Watanabe A, Aburatani H, Yoshida K, Ishi K, Takamori K, Ogawa H, Hamakubo T, Kodama T, Araki Y. Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int. J. Gynecol. Cancer, 17, 1300-1306 (2007).
4. Heringlake S, Hofdmann M, Fiebeler A, Manns MP, Schmiegel W, Tannapfel A. Identification and expression analysis of the aldoketoreductase1-B10 gene in primary malignant liver tumours. J. Hepatol., 52, 220-227 (2010).
5. Chung YT, Matkowskyj KA, Li H, Bai H, Zhang W, Tsao MS, Liao J, Yang GY. Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. Mod. Pathol., 25, 758-766 (2012).
6. Ma J, Luo DX, Huang C, Shen Y, Bu Y, Markwell S, Gao J, Liu J, Zu X, Cao Z, Gao Z, Lu F, Liao DF, Cao D. AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker. Int. J. Cancer, 131, E862-E871 (2012).
7. Yan R, Zu X, Ma J, Liu Z, Adeyanju M, Cao D. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention. Int. J. Cancer, 121, 2301-2306 (2007).
8. Wang C, Yan R, Luo D, Watabe K, Liao DF, Cao D. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J. Biol. Chem., 284, 26742-26748 (2009).
9. Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, Honda K, Kosuge T, Ochiya T, Hirohashi S, Yamada T. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin. Cancer Res., 16, 2518-2528 (2010).
10. Soda M, Hu D, Endo S, Takemura M, Li J, Wada R, Ifuku S, Zhao HT, El-Kabbani O, Ohta S, Yamamura K, Toyooka N, Hara A, Matsunaga T. Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10. Eur. J. Med. Chem., 48, 321-329 (2012).
11. Matsunaga T, Wada Y, Endo S, Soda M, El-Kabbani O, Hara A. Aldo-keto reductase 1B10 and its role in proliferation capacity of drug-resistant cancers. Front. Pharmacol., 3, 5 (2012).
12. Crosas B, Hyndman DJ, Gallego O, Martras S, Parés X, Flynn TG, Farrés J. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem. J., 373, 973-979 (2003).
13. Endo S, Matsunaga T, Mamiya H, Ohta C, Soda M, Kitade Y, Tajima K, Zhao HT, El-Kabbani O, Hara A. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids. Arch. Biochem. Biophys., 487, 1-9 (2009).
14. Baba SP, Barski OA, Ahmed Y, O'Toole TE, Conklin DJ, Bhatnagar A, Srivastava S. Reductive metabolism of AGE precursors: a metabolic route for preventing AGE accumulation in cardiovascular tissue. Diabetes, 58, 2486-2497 (2009).
15. 2 synthase activity in the absence of NADP(H). FEBS J., 278, 1288-1298 (2011).
16. Takemura M, Endo S, Matsunaga T, Soda M, Zhao HT, El-Kabbani O, Tajima K, Iinuma M, Hara A. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid. J. Nat. Prod., 74, 1201-1206 (2011).
17. Moriguchi H, Zhang Y, Mihara M, Sato C. A therapeutic method for the direct reprogramming of human liver cancer cells with only chemicals. Sci. Rep., 2, 280 (2012).
18. Matsunaga T, Endo S, Soda M, Zhao HT, El-Kabbani O, Tajima K, Hara A. Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis. Biochem. Biophys. Res. Commun., 389, 128-132 (2009).
19. Akao Y, Nakagawa Y, Iinuma M, Nozawa Y. Anti-cancer effects of xanthones from pericarps of mangosteen. Int. J. Mol. Sci., 9, 355-370 (2008).
20. Shan T, Ma Q, Guo K, Liu J, Li W, Wang F, Wu E. Xanthones from mangosteen extracts as natural chemopreventive agents: potential anticancer drugs. Curr. Mol. Med., 11, 666-677 (2011).
21. Asai F, Tosa H, Tanaka T, Iinuma M. A xanthone from pericarps of Garcinia mangostana. Phytochemistry, 39, 943-944 (1995).
22. Endo S, Matsunaga T, Soda M, Tajima K, Zhao HT, El-Kabbani O, Hara A. Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid. Biol. Pharm. Bull., 33, 886-890 (2010).
23. Iino T, Tabata M, Takikawa S, Sawada H, Shintaku H, Ishikura S, Hara A. Tetrahydrobiopterin is synthesized from 6-pyruvoyl-tetrahydropterin by the human aldo-keto reductase AKR1 family members. Arch. Biochem. Biophys., 416, 180-187 (2003).
24. Gallego O, Ruiz FX, Ardèvol A, Domínguez M, Alvarez R, de Lera AR, Rovira C, Farrés J, Fita I, Parés X. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc. Natl. Acad. Sci. U.S.A., 104, 20764-20769 (2007).
25. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem., 47, 1739-1749 (2004).
26. Endo S, Matsunaga T, Kuwata K, Zhao HT, El-Kabbani O, Kitade Y, Hara A. Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10. Bioorg. Med. Chem., 18, 2485-2490 (2010).
27. Díez-Dacal B, Gayarre J, Gharbi S, Timms JF, Coderch C, Gago F, Pérez-Sala D. Identification of aldo-keto reductase AKR1B10 as a selective target for modification and inhibition by prostaglandin A(1): Implications for antitumoral activity. Cancer Res., 71, 4161-4171 (2011).
28. Balendiran GK, Martin HJ, El-Hawari Y, Maser E. Cancer biomarker AKR1B10 and carbonyl metabolism. Chem. Biol. Interact., 178, 134-137 (2009).
29. Zhao HT, Soda M, Endo S, Hara A, El-Kabbani O. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening. Eur. J. Med. Chem., 45, 4354-4357 (2010).
30. Pedraza-Chaverri J, Cárdenas-Rodríguez N, Orozco-Ibarra M, Pérez-Rojas JM. Medicinal properties of mangosteen (Garcinia mangostana). Food Chem. Toxicol., 46, 3227-3239 (2008).
31. Jiang HZ, Quan XF, Tian WX, Hu JM, Wang PC, Huang SZ, Cheng ZQ, Liang WJ, Zhou J, Ma XF, Zhao YX. Fatty acid synthase inhibitors of phenolic constituents isolated from Garcinia mangostana. Bioorg. Med. Chem. Lett., 20, 6045-6047 (2010).
32. Foti RS, Pearson JT, Rock DA, Wahlstrom JL, Wienkers LC. In vitro inhibition of multiple cytochrome P450 isoforms by xanthone derivatives from mangosteen extract. Drug Metab. Dispos., 37, 1848-1855 (2009).
33. Deschamps JD, Gautschi JT, Whitman S, Johnson TA, Gassner NC, Crews P, Holman TR. Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg. Med. Chem., 15, 6900-6908 (2007).
34. Okudaira C, Ikeda Y, Kondo S, Furuya S, Hirabayashi Y, Koyano T, Saito Y, Umezawa K. Inhibition of acidic sphingomyelinase by xanthone compounds isolated from Garcinia speciosa. J. Enzyme Inhib., 15, 129-138 (2000).
35. 2+-pumping ATPase from rabbit skeletal muscle. Jpn. J. Pharmacol., 71, 337-340 (1996).
36. Balunas MJ, Su B, Brueggemeier RW, Kinghorn AD. Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. J. Nat. Prod., 71, 1161-1166 (2008).
37. Chen SX, Wan M, Loh BN. Active constituents against HIV-1 protease from Garcinia mangostana. Planta Med., 62, 381-382 (1996).
38. Jinsart W, Ternai B, Buddhasukh D, Polya GM. Inhibition of wheat embryo calcium-dependent protein kinase and other kinases by mangostin and γ-mangostin. Phytochemistry, 31, 3711-3713 (1992).
39. Nakatani K, Yamakuni T, Kondo N, Arakawa T, Oosawa K, Shimura S, Inoue H, Ohizumi Y. γ-Mangostin inhibits inhibitor-kappaB kinase activity and decreases lipopolysaccharide-induced cyclooxygenase-2 gene expression in C6 rat glioma cells. Mol. Pharmacol., 66, 667-674 (2004).
40. 2 synthesis by γ-mangostin, a xanthone derivative in mangosteen, in C6 rat glioma cells. Biochem. Pharmacol., 63, 73-79 (2002).